German biotechnology company BioNTech SE (Nasdaq:BNTX) reported on Monday total revenue of EUR3.2bn for the second quarter of 2022, down from EUR5.3bn in the same period a year ago.
In the first six months of the year, total revenue grew to EUR9.6bn from EUR7.4bn a year earlier.
Net profit for the second quarter amounted to EUR1.7bn, compared with EUR2.8bn in the second quarter last year, with the first-half figures showing an increase to EUR5.4bn from EUR3.9bn in the first six months of 2021.
The company fell short of sales and earnings expectations in the second quarter after the European Commission renegotiated its COVID-19 vaccine contract. Doses scheduled for delivery in June-August 2022 will now be delivered in September through to the fourth quarter of 2022. This change of delivery schedule did not impact the company's full-year 2022 revenue guidance or the full-year commitment of doses to be delivered to EU member states in 2022.
BioNTech also said that, with its partner Pfizer Inc (NYSE:PFE), it plans to launch a clinical trial this month of a COVID-19 vaccine adapted to the BA.4 and BA.5 variants of Omicron.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma